Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Session at AAPS National Biotechnology Conference to Cover Gene & Therapy Market | Contract Pharma

What are you searching for?

Sign in
Breaking News

Session at AAPS National Biotechnology Conference to Cover Gene & Therapy Market

‘Cell and Gene Therapies at the Intersection of Business and Science,’ will take place on May 14 at 9:30 a.m. in San Francisco.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

The exclusive executive track session, “Cell and Gene Therapies at the Intersection of Business and Science,” will take place on May 14 at 9:30 a.m. during the AAPS National Biotechnology Conference (NBC) in San Francisco.
 
Potens Pharmaceuticals Founder Praveen Tyle, Ph.D., will moderate a panel focused on the current state of cell and gene therapies. The discussion will center on practical insights into how biotech leaders are addressing market pain points, e.g., global market access, development speed, and organizational capabilities. Other discussion points include business considerations and their intersection with scientific advancement, and how demand for these advanced therapeutics impacts global health.
 
“Cell and gene therapies represent the future of biotherapeutic drug development,” said Dr. Tyle, who is also Vice Chair of AAPS’s Business and Partner Development Committee. “Overcoming current challenges to ensure continued growth of these products requires science’s business leaders to come together and work collaboratively across the industry. I’m honored to facilitate this discussion at the NBC.”
 
Jason Bock, Ph.D., Co-Founder and CEO of the Cell Therapy Manufacturing Center (CTMC), Nianwei Lin, Ph.D., Co-Founder and President at iXCells Biotechnologies, and Kimberley Buytaert-Hoefen, Ph.D., Executive Director and Global Head of Regulatory Services at QPS, are confirmed to speak in this session.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters